Compare · COR vs HKPD
COR vs HKPD
Side-by-side comparison of Cencora Inc. (COR) and Cellyan Biotechnology Co. Ltd (HKPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and HKPD operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $65.15B, about 12223.0x HKPD ($5.3M).
- COR has been more active in the news (6 items in the past 4 weeks vs 2 for HKPD).
- COR has more recent analyst coverage (25 ratings vs 0 for HKPD).
- Company
- Cencora Inc.
- Cellyan Biotechnology Co. Ltd
- Price
- -
- -
- Market cap
- $65.15B
- $5.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 0
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
Latest COR
- SEC Form 4 filed by Cencora Inc.
- SEC Form 4 filed by Cencora Inc.
- Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
- New insider Sanchez Robert E claimed ownership of 197 shares (SEC Form 3)
- Cencora Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Elects Robert E. Sanchez to Its Board of Directors
- Director Greenberg Lon R sold $411,264 worth of shares (1,280 units at $321.30), decreasing direct ownership by 7% to 17,128 units (SEC Form 4)
- SVP & Chief Accounting Officer Krikorian Lazarus sold $321,080 worth of shares (985 units at $325.97) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 16,169 units (SEC Form 4)
- Executive Vice President Campbell Elizabeth S sold $3,662,663 worth of shares (11,300 units at $324.12), decreasing direct ownership by 37% to 19,455 units (SEC Form 4)
- RBC Capital Mkts initiated coverage on Cencora with a new price target
Latest HKPD
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form S-8 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 20-F filed by Cellyan Biotechnology Co. Ltd
- SEC Form NT 20-F filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
- SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
- SEC Form F-3 filed by Cellyan Biotechnology Co. Ltd